<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">clinvest</journal-id><journal-title-group><journal-title xml:lang="ru">Качественная клиническая практика</journal-title><trans-title-group xml:lang="en"><trans-title>Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2588-0519</issn><issn pub-type="epub">2618-8473</issn><publisher><publisher-name>ООО «Издательство ОКИ</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37489/2588-0519-2022-2-21-27</article-id><article-id custom-type="elpub" pub-id-type="custom">clinvest-614</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИССЛЕДОВАНИЯ РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REAL-WORLD STUDIES</subject></subj-group></article-categories><title-group><article-title>Внешний контроль при проведении исследований RWD/RWE: методологический подход</article-title><trans-title-group xml:lang="en"><trans-title>External control during RWD/RWE research: a methodological approach</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2628-6003</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Журавков</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhuravkov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Журавков Андрей Андреевич - аспирант кафедры клинической фармакологии и доказательной медицины.</p><p>Санкт-Петербург.</p></bio><bio xml:lang="en"><p>Andrei A. Zhuravkov - Post-graduate student, Department of Clinical Pharmacology and Evidence-Based Medicine I.P. Pavlov SPbSMU MOH Russia.</p><p>Saint-Petersburg.</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1919-2909</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Колбин</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kolbin</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Колбин Алексей Сергеевич – доктор медицинских наук, профессор, заведующий кафедрой клинической фармакологии и доказательной медицины.</p><p>Санкт-Петербург.</p><p>SPIN-код: 7966-0845</p></bio><bio xml:lang="en"><p>Alexey S. Kolbin - Dr. Sci. (Med.), Professor, Head of the Department of Clinical Pharmacology and Evidence-Based Medicine, I.P. Pavlov SPbSMU MOH Russia.</p><p>Saint-Petersburg.</p><p>SPIN code: 7966-0845</p></bio><email xlink:type="simple">alex.kolbin@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Academician I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>02</day><month>08</month><year>2022</year></pub-date><volume>0</volume><issue>2</issue><fpage>21</fpage><lpage>27</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Журавков А.А., Колбин А.С., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Журавков А.А., Колбин А.С.</copyright-holder><copyright-holder xml:lang="en">Zhuravkov A.A., Kolbin A.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.clinvest.ru/jour/article/view/614">https://www.clinvest.ru/jour/article/view/614</self-uri><abstract><p>На данный момент золотым стандартом для представления доказательств эффективности и безопасности лекарственных препаратов являются рандомизированные контролируемые исследования (РКИ). В случае невозможности рандомизации и создания внутренней контрольной группы применяют альтернативные методы сбора доказательств, например использование так называемых внешних контрольных групп, созданных в том числе на основании данных реальной  клинической  практики  (real  world  data  (RWD)).  Рост  количества  исследований  с  использованием  RWD  и внешнего контроля чётко прослеживается в онкологии, где классически существуют проблемы с рандомизацией. Между тем такая тенденция вызывает обеспокоенность и требует лучшего понимания приемлемости использования внешних контрольных групп и валидации RWD.</p></abstract><trans-abstract xml:lang="en"><p>At the moment, randomized controlled trials (RCTs) are the gold standard for providing evidence of the effectiveness and safety of medicines. If it is impossible to randomize and create an internal control group, alternative methods of collecting evidence are used, for example, the use of so-called external control groups created, among other things, based on real world data (RWD). The increase in the number of studies using RWD and external control is clearly visible in oncology, where there are problems with randomization classically. Meanwhile, this trend is of concern and requires a better understanding of the acceptability of using external control groups and validation of RWD.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>реальная клиническая практика</kwd><kwd>RWD</kwd><kwd>внешний контроль</kwd></kwd-group><kwd-group xml:lang="en"><kwd>real-world data</kwd><kwd>RWD</kwd><kwd>external control</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">About Date. Объём данных всего мира к 2025 году увеличится в 10 раз [Электронный ресурс]. — Доступ по ссылке: https://aboutdata.ru/2017/04/27/volume-of-data-by-2025/ (доступ от 03.04.2022).</mixed-citation><mixed-citation xml:lang="en">About Date. Объём данных всего мира к 2025 году увеличится в 10 раз [Электронный ресурс]. — Доступ по ссылке: https://aboutdata.ru/2017/04/27/volume-of-data-by-2025/ (доступ от 03.04.2022).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Grootendorst DC, Jager KJ, Zoccali C, Dekker FW. Observational studies are complementary to randomized controlled trials. Nephron Clin Pract. 2010;114(3):c173-7. doi: 10.1159/000262299</mixed-citation><mixed-citation xml:lang="en">Grootendorst DC, Jager KJ, Zoccali C, Dekker FW. Observational studies are complementary to randomized controlled trials. Nephron Clin Pract. 2010;114(3):c173-7. doi: 10.1159/000262299</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Eichler HG, Abadie E, Breckenridge A et al. Bridging the efficacy— effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat Rev Drug Discov. 2011:10(7);495–506. doi: 10.1038/nrd3501</mixed-citation><mixed-citation xml:lang="en">Eichler HG, Abadie E, Breckenridge A et al. Bridging the efficacy— effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat Rev Drug Discov. 2011:10(7);495–506. doi: 10.1038/nrd3501</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Woolery L, Grzymala-Busse J, Summers S, Budihardjo A. The use of machine learning program LERS-LB 2.5 in knowledge acquisition for expert system development in nursing. Comput Nurs. 1991;9(6):227-34.</mixed-citation><mixed-citation xml:lang="en">Woolery L, Grzymala-Busse J, Summers S, Budihardjo A. The use of machine learning program LERS-LB 2.5 in knowledge acquisition for expert system development in nursing. Comput Nurs. 1991;9(6):227-34.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Makady A, de Boer A, Hillege H, et al. What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews. Value Health. 2017;20(7):858–65. doi: 10.1016/j.jval.2017.03.008</mixed-citation><mixed-citation xml:lang="en">Makady A, de Boer A, Hillege H, et al. What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews. Value Health. 2017;20(7):858–65. doi: 10.1016/j.jval.2017.03.008</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Солодовников А.Г., Сорокина Е.Ю., Гольдина Т.А. Данные рутинной практики (real-world data): от планирования к анализу. Медицинские технологии. Оценка и выбор. 2020;41(3):9–16. doi: 10.17116/medtech2020410319</mixed-citation><mixed-citation xml:lang="en">Solodovnikov AG, Sorokina EYu, Goldina TA. Real-world data: from planning to analysis. Medical Technologies. Assessment and Choice. 2020;41(3):9–16. (In Russ). doi: 10.17116/medtech2020410319</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Решение Совета Евразийской экономической комиссии от 17 марта 2022 г. N 36 «О внесении изменений в Правила регистрации и экспертизы лекарственных средств для медицинского применения».</mixed-citation><mixed-citation xml:lang="en">Reshenie Soveta Evrazijskoj ekonomicheskoj komissii ot 17 marta 2022 g. N 36 «O vnesenii izmenenij v Pravila registracii i ekspertizy lekarstvennyh sredstv dlya medicinskogo primeneniya» (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Колбин А. С. Зачем нужен новый научный электронный журнал «Реальная клиническая практика: данные и доказательства»? Реальная клиническая практика: данные и доказательства. 2021;1(1). doi: 10.37489/2782-3784-myrwd-1</mixed-citation><mixed-citation xml:lang="en">Kolbin AS. Why do we need «Real-World Data &amp; Evidence», the new scientific electronic journal? Real-World Data &amp; Evidence. 2021;1(1). (In Russ). doi: 10.37489/2782-3784-myrwd-1</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Mishra-Kalyani PS, Amiri Kordestani L, Rivera DR, Singh H, Ibrahim A, DeClaro RA, Shen Y, Tang S, Sridhara R, Kluetz PG, Concato J, Pazdur R, Beaver JA. External control arms in oncology: current use and future directions. Ann Oncol. 2022 Apr;33(4):376–83. doi: 10.1016/j.annonc.2021.12.015</mixed-citation><mixed-citation xml:lang="en">Mishra-Kalyani PS, Amiri Kordestani L, Rivera DR, Singh H, Ibrahim A, DeClaro RA, Shen Y, Tang S, Sridhara R, Kluetz PG, Concato J, Pazdur R, Beaver JA. External control arms in oncology: current use and future directions. Ann Oncol. 2022 Apr;33(4):376–83. doi: 10.1016/j.annonc.2021.12.015</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Friends of Cancer Research 2019 Annual Meeting Panel Presentation. Characterizing the use of external controls for augmenting randomized control arms and confirming benefit.</mixed-citation><mixed-citation xml:lang="en">Friends of Cancer Research 2019 Annual Meeting Panel Presentation. Characterizing the use of external controls for augmenting randomized control arms and confirming benefit.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Jahanshahi M, Gregg K, Davis G, Ndu A, Miller V, Vockley J, Ollivier C, Franolic T, Sakai S. The Use of External Controls in FDA Regulatory Decision Making. Ther Innov Regul Sci. 2021 Sep;55(5):1019–35. doi: 10.1007/s43441-021-00302-y</mixed-citation><mixed-citation xml:lang="en">Jahanshahi M, Gregg K, Davis G, Ndu A, Miller V, Vockley J, Ollivier C, Franolic T, Sakai S. The Use of External Controls in FDA Regulatory Decision Making. Ther Innov Regul Sci. 2021 Sep;55(5):1019–35. doi: 10.1007/s43441-021-00302-y</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Thorlund K, Dron L, Park JJH, Mills EJ. Synthetic and External Controls in Clinical Trials — A Primer for Researchers. Clin Epidemiol. 2020 May 8;12:457–67. doi: 10.2147/CLEP.S242097</mixed-citation><mixed-citation xml:lang="en">Thorlund K, Dron L, Park JJH, Mills EJ. Synthetic and External Controls in Clinical Trials — A Primer for Researchers. Clin Epidemiol. 2020 May 8;12:457–67. doi: 10.2147/CLEP.S242097</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Busgang SA, Waller LA, Colicino E, D’Agostino R Jr, Hertz-Picciotto I, Gennings C. Selecting External Controls for Internal Cases Using Stratification Score Matching Methods. Int J Environ Res Public Health. 2022 Feb 23;19(5):2549. doi: 10.3390/ijerph19052549</mixed-citation><mixed-citation xml:lang="en">Busgang SA, Waller LA, Colicino E, D’Agostino R Jr, Hertz-Picciotto I, Gennings C. Selecting External Controls for Internal Cases Using Stratification Score Matching Methods. Int J Environ Res Public Health. 2022 Feb 23;19(5):2549. doi: 10.3390/ijerph19052549</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Колбин А. С. От имени рабочей группы по RWD/RWE в Российской Федерации. Резолюция по результатам работы конференции: «RWD/RWE — Инструменты исследования реальной клинической практики: сегодня и завтра». Реальная клиническая практика: данные и доказательства. 2021;1(1):21–4. doi: 10.37489/2782-3784-myrwd-5</mixed-citation><mixed-citation xml:lang="en">-Kolbin AS. Resolution based on the results of the conference: «RWD/ RWE — Research Tools of Real-World Clinical Practice Today and Tomorrow». Real-World Data &amp; Evidence. 2021;1(1). (In Russ). doi: 10.37489/2782-3784-myrwd-5</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
